- Home
- STEC vs SPRO Comparison
STEC vs SPRO Comparison
Compare STEC & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- SPRO
- Stock Information
- Founded
- STEC 2006
- SPRO 2013
- Country
- STEC China
- SPRO United States
- Employees
- STEC N/A
- SPRO N/A
- Industry
- STEC
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- SPRO Health Care
- Exchange
- STEC NYSE
- SPRO Nasdaq
- Market Cap
- STEC 29.7M
- SPRO 164.4M
- IPO Year
- STEC 2021
- SPRO 2017
- Fundamental
- Price
- STEC $0.89
- SPRO $2.93
- Analyst Decision
- STEC
- SPRO Buy
- Analyst Count
- STEC 0
- SPRO 4
- Target Price
- STEC N/A
- SPRO $5.00
- AVG Volume (30 Days)
- STEC 15.1K
- SPRO 2.1M
- Earning Date
- STEC 07-07-2025
- SPRO 08-04-2025
- Dividend Yield
- STEC N/A
- SPRO N/A
- EPS Growth
- STEC N/A
- SPRO N/A
- EPS
- STEC N/A
- SPRO N/A
- Revenue
- STEC $10,672,000.00
- SPRO $44,584,000.00
- Revenue This Year
- STEC $9,392.20
- SPRO N/A
- Revenue Next Year
- STEC N/A
- SPRO N/A
- P/E Ratio
- STEC N/A
- SPRO N/A
- Revenue Growth
- STEC N/A
- SPRO N/A
- 52 Week Low
- STEC $0.20
- SPRO $0.51
- 52 Week High
- STEC $3.25
- SPRO $3.09
- Technical
- Relative Strength Index (RSI)
- STEC 44.88
- SPRO 72.09
- Support Level
- STEC $0.76
- SPRO $2.79
- Resistance Level
- STEC $1.00
- SPRO $3.09
- Average True Range (ATR)
- STEC 0.10
- SPRO 0.15
- MACD
- STEC -0.01
- SPRO -0.07
- Stochastic Oscillator
- STEC 32.25
- SPRO 64.44
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.